Results 41 to 50 of about 38,752 (185)

Distinct types of VHHs in Alpaca

Frontiers in Immunology
IntroductionVHHs (VH of heavy-chain-only antibodies) represent a unique alternative to Q7 conventional antibodies because of their smaller size, comparable binding affinity and biophysical properties. MethodIn this study, we systematically analyzed VHH NGS sequences from 22 Alpacas and structure data from public database.
Xinhao Wang, Lu Zhang, Yao Zhang, Jiaguo Li, Wenfeng Xu, Weimin Zhu   +5 more
openaire   +3 more sources

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

Advanced Science, EarlyView.
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo, Yijuan Wang, Dengwang Chen, Yinghan Zhang, Yi Shuai, Hualiang Yao, Tao Jiang, Hang Jiang, Ming Zhong, Xiangeng Wang, Ziwei Wang, Chenchen Xu, Ajay Goel, Hoi Tang MA, Feng Gao, Xin Wang   +15 more
wiley   +1 more source

Programmable Nanobody‐Targeting Chimeras Enable Intracellular Viral Protein Degradation

Advanced Science, EarlyView.
Nab‐TAC enables targeted degradation of HBV surface antigen (HBsAg) in vivo. By fusing nanobody‐based recognition domains with programmable proteasome‐recruiting degradation signals, Nab‐TAC reduces HBsAg levels in a hydrodynamic HBV mouse model. ABSTRACT Chronic hepatitis B virus (HBV) infection remains a major global health challenge, largely because
Max Yu‐Chen Pan, Ting‐Hui Lee, Tzu‐Ning Peng, Eva Yi‐Hsuan Wu, Yu‐Ting Chiu, Chih‐Chien Chiu, Hong Vinh Nguyen, Yuan‐Shao Pao, Ming‐Hong Chao, Richard Kuan‐Lin Lee, Han‐Chung Wu, Lily Hui‐Ching Wang   +11 more
wiley   +1 more source

Isolation of Novel EGFR-Specific VHH Domains [PDF]

SLAS Discovery, 2009
Epidermal growth factor receptor (EGFR) is overexpressed or mutated in a high percentage of tumors. EGFR has long been considered a promising target for cancer diagnostic and therapeutic applications. However, monoclonal antibodies and other large antibody constructs diffuse into tumors slowly, limiting their efficacy. To develop lower molecular weight
Elizabeth B, Gottlin, , Xiangrong Guan, Charles, Pegram, Allen, Cannedy, Michael J, Campa, Edward F, Patz   +5 more
openaire   +2 more sources

Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders

Advanced Science, EarlyView.
Antibody can be engineered into diverse lysosome‐targeting chimeras that convert target recognition into active degradation. By coupling antibody binding with recruited receptors, encoded domains, conjugated ligands, or nanoparticle scaffolds, these antibody‐associated targeted chimeras (AbTACs) platforms direct extracellular and membrane proteins ...
Kaige Chen, Quanyin Hu
wiley   +1 more source

Relationship Between Hospital Volume and Outcomes of Minimally Invasive Esophagectomy for Esophageal Cancer: Analysis of the National Clinical Database in Japan

Annals of Gastroenterological Surgery, EarlyView.
According to multivariable analysis conducted using a hierarchical logistic regression model, using VHH as the reference group, the odds ratios for mortality by hospital volume category were as follows: VLH, 2.70 (p < 0.0001); LH, 1.72 (p = 0.052); MH, 1.70 (p = 0.034); and HH, 1.43 (p = 0.173).
Soji Ozawa, Hiraku Kumamaru, Yuko Kitagawa, Kazuo Koyanagi, Junya Oguma, Harushi Udagawa, Hiroaki Miyata, Yasushi Toh, Hisahiro Matsubara   +8 more
wiley   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Nanobody and Its Therapeutic Applications

Journal of Mazandaran University of Medical Sciences, 2018
Background and purpose: Monoclonal antibodies market has grown since approval of Muromonab-CD3 (trade name Orthoclone OKT3) in 1986 as immuno- suppressor.
Maryam Darvish
doaj  

Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes

Antibodies, 2019
Broad and potent neutralizing llama single domain antibodies (VHH) against HIV-1 targeting the CD4 binding site (CD4bs) have previously been isolated upon llama immunization.
Nika M. Strokappe, Miriam Hock, Lucy Rutten, Laura E. Mccoy, Jaap W. Back, Christophe Caillat, Matthias Haffke, Robin A. Weiss, Winfried Weissenhorn, Theo Verrips   +9 more
doaj   +1 more source